secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0000950170-24-088578
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q2 revenue $37.2M, net loss $45.7M; FY2024 guidance cut to $170-175M
--------------------------------------------------------------------------------

- Q2 revenue $37.2M (pro forma combined -23% YoY); net loss $45.7M; adjusted EBITDA loss $31.0M.
- FY2024 revenue guidance reduced to $170-$175M from prior expectation; cites weaker SomaScan services and capital spending slowdown.
- Accelerated merger synergy target: $80M cost reductions expected operationalized by end of 2024, a year ahead of plan.
- Repurchased ~11.3M shares in Q2 for ~$29M at avg $2.57/share; cash position $396M.
- Revenue decline primarily from timing of large customer projects in Europe and constrained capital purchase environment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095017024088578/0000950170-24-088578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095017024088578/lab-20240731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer